Prospective, multicenter study for prediction of therapeutic effect of FOLFIRINOX with analyzing 5FU metabolism to aim the tailor-made therapy for unresectable pancreatic cancer.
Not Applicable
Recruiting
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000027009
- Lead Sponsor
- Okayama university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Homotype of UGT1A1 genotype including *28/*28, *6/*6 and*6/*28 Evident pleural effusion, ascites, pericardial effusion or peritoneal metastasis on CT before enrollment Pulmonary fibrosis or interstitial pneumonia Watery stool within 3 days before enrollment Uncontrolled diabetes mellitus Any serious complication
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method